NMD4C at Ottawa NMD 2023
This September 7th to 9th the University of Ottawa Éric Poulin Centre for Neuromuscular Disease (CNMD) hosted the 6th Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023), with a program emphasizing recent breakthroughs in basic and translational research and clinical discoveries in neuromuscular disease. As a network, we had the opportunity to present three posters on the outcomes of select network activities from the first NMD4C grant period. Read the NMD4C abstracts here. All of the Ottawa NMD abstracts are also available on the event website. We also hosted a booth at the conference to share information on the network, recruit new members, and discuss our work with the many investigators and neuromuscular stakeholders who visited!
NMD4C Posters at Ottawa NMD 2023
- Compliance to Duchenne Muscular Dystrophy Care Considerations in Canada
- Expert Patient Capacity Building in Neuromuscular Disease Research
- The Neuromuscular Disease Network for Canada (NMD4C): An interdisciplinary national collaboration to tackle unmet needs for NMD research and care
Read the NMD4C abstracts here.
NMD4C Investigators that Presented at Ottawa NMD 2023
The three-day Ottawa NMD 2023 conference hosted nationally and internationally renowned basic researchers and clinicians to present talks highlighting advances in all aspects of NMD research, including new clinical diagnostic techniques, biology of disease pathogenesis, basic muscle and stem cell biology, and promising therapies to treat NMDs. Several network investigators delivered talks across the action-packed three-day program.
- Dr Craig Campbell: Duchenne Muscular Dystrophy Episignature
- Dr Natasha Chang: Muscle stem cell dysfunction in Duchenne muscular dystrophy
- Dr Gerald Pfeffer: Transcriptomic profiles and pathologic correlation in adult-onset myopathies
- Dr Hernan Gonorazky: MRI in the age of Artificial Intelligence
- Dr Mireille Khacho: Impact of Mitochondrial Dynamics on Muscle Stem Cell Function: Insights from Physiology, Diseases and Ageing
- Dr Hanns Lochmüller: Congenital myasthenic syndromes – diagnosis and therapy
- Dr Rami Massie: Update in autoimmune neuropathies
- Dr Hugh McMillan: Gene therapy in spinal muscular atrophy
- Dr Kerri Schellenberg: Clinical Updates in Spinal Bulbar Muscular Atrophy
- Dr Jodi Warman Chardon: Muscle Imaging in Genetic and Autoimmune Muscle Diseases
- Dr Nicolas Dumont: Clearance of defective muscle stem cells by senolytics reduces the expression of senescence associated secretory phenotype and restores myogenesis in myotonic dystrophy type 1
- Stacey Lintern / Dr Homira Osman: Opening remarks at Keynote Session
We are looking forward to Ottawa NMD 2025!
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.